COMMUNIQUÉ DE PRESSE publié le 23/07/2025 à 14:30, il y a 10 mois 30 jours Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRÈVE publiée le 08/07/2025 à 15:05, il y a 11 mois 14 jours Xenetic Biosciences Updates on DNase I Study Collaboration Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
BRÈVE publiée le 08/07/2025 à 15:05, il y a 11 mois 14 jours Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
COMMUNIQUÉ DE PRESSE publié le 08/07/2025 à 15:00, il y a 11 mois 14 jours Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRÈVE publiée le 14/05/2025 à 14:10, il y a 1 année 1 mois Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025 Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRÈVE publiée le 14/05/2025 à 14:10, il y a 1 année 1 mois Xenetic Biosciences Reports Q1 2025 Financial Results Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
COMMUNIQUÉ DE PRESSE publié le 14/05/2025 à 14:05, il y a 1 année 1 mois Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I
BRÈVE publiée le 09/04/2025 à 15:20, il y a 1 année 2 mois Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting Xenetic Biosciences Preclinical Data Solid Tumors DNase Technology CAR-T Cell Therapy
BRÈVE publiée le 09/04/2025 à 15:20, il y a 1 année 2 mois Xenetic Biosciences partage des données précliniques prometteuses lors de la réunion du SITC Biosciences Xénétiques Thérapie Cellulaire CAR-T Tumeurs Solides Données Précliniques Technologie DNase
COMMUNIQUÉ DE PRESSE publié le 09/04/2025 à 15:15, il y a 1 année 2 mois Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website Immuno-oncology Xenetic DNase I SITC 2025 CAR-T Cell Therapy
Publié le 22/06/2026 à 18:00, il y a 7 heures 19 minutes GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION
Publié le 22/06/2026 à 23:25, il y a 1 heure 54 minutes Infield Minerals Announces Intention to Issue Shares for Kings Canyon Gold Property Option Payment
Publié le 22/06/2026 à 23:05, il y a 2 heures 14 minutes Gamma Resources Settles Remaining Balance of Outstanding Debt
Publié le 22/06/2026 à 21:05, il y a 4 heures 14 minutes RUM Announces Voting Results From Annual General Meeting of Shareholders
Publié le 22/06/2026 à 19:45, il y a 5 heures 34 minutes Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Publié le 22/06/2026 à 15:58, il y a 9 heures 21 minutes Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Publié le 22/06/2026 à 21:07, il y a 4 heures 12 minutes EQS-Adhoc: RWE Aktiengesellschaft: RWE sets placement price for shares from capital measure and raises gross proceeds of 4 billion EUR
Publié le 22/06/2026 à 20:50, il y a 4 heures 29 minutes Ethlabs, Founded by Former Ethereum Foundation Contributors and Funded by Bitmine, Sharplink and Joe Lubin, Launches to Accelerate Ethereum's Institutional Supercycle
Publié le 22/06/2026 à 20:32, il y a 4 heures 47 minutes EQS-Adhoc: Deutsche Konsum Real Estate AG: Daniel Löhken appointed Chief Executive Officer of the Company and Dr Kai Gregor Klinger appointed new Chairman of the Supervisory Board
Publié le 22/06/2026 à 19:27, il y a 5 heures 52 minutes Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Publié le 22/06/2026 à 18:54, il y a 6 heures 25 minutes EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026